Stanford University
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.
Postural Tachycardia Syndrome (POTS) is a heterogeneous condition affecting approximately 0.2% of the global population, predominantly young women of childbearing age. It is characterized by significant functional impairment and a constellation of symptoms, including lightheadedness, cognitive dysfunction, blurred vision, irritability, palpitations, and chest discomfort, which occur upon standing and improve when lying down. Although current pharmacological and non-pharmacological treatments alleviate symptoms for some patients, many remain significantly disabled. These challenges highlight th…
Inclusion Criteria: * Adult patients (\>18 years of age) diagnosed with POTS * Ability to provide informed consent * Ability to comply with 3 follow up visits * English speaking and capable of signing informed consent and complying with protocol requirements Exclusion Criteria: * Allergy to local anesthetics * Severe coagulopathy * History of or currently being treated for clinically significant ongoing cardiac arrhythmia, heart failure, myocarditis, pulmonary embolism requiring anticoagulation, pulmonary fibrosis or other pulmonary diagnosis that in the investigator's opinion may contribut…
Patients will receive a SGB
Patients will receive a subcutaneous sham injection of saline
The SGB group will receive ropivacaine 0.5% 10ml
The control group will receive normal saline in the sham injection.
Arctuva estimate
Verify or correct the compensation shown for this listing.